- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6168
Provisional Schedule
- Committee meeting: 1:
- 12 November 2025
- Expected publication:
- 04 February 2026
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Centre for Reviews and Dissemination and Centre for Health Economics, University of York
Stakeholders
- Companies sponsors
- AstraZeneca
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Action Bladder Cancer UK
- Fight Bladder Cancer
- Professional groups
- Association of Cancer Physicians
- British Uro-Oncology Group
- Cancer Research UK
- Royal College of Physicians
- Comparator companies
- Bristol Myers Squibb (nivolumab) – not participating
- Hospira UK (cisplatin, gemcitabine) – not participating
- Ranbaxy UK (Sun Pharma) (gemcitabine) – not participating
- Sandoz (cisplatin) – not participating
- Synchrony Pharma (CNX Therapeutics) (gemcitabine) – not participating
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health – Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 14 April 2025 | Invitation to participate |
| 20 February 2025 | In progress. Scoping commenced. |
| 20 January 2025 - 17 February 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6168 |
| 11 August 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual